Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on August 15, 2018. The report covers a specific corporate event occurring on the same date regarding the company's drug development pipeline.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the approval of the United States Adopted Name (USAN) for the company's drug candidate, PCM-075. The USAN Council approved "Onvansertib" as the nonproprietary (generic) name.
Outlook, Commentary, and Risks
Management commentary highlights that Onvansertib is a first-in-class, 3rd generation, highly selective, oral Polo Like Kinase 1 (PLK1) inhibitor designed to target and inhibit cancer cell division (mitosis). The filing does not explicitly list new risks, contingencies, or unusual items beyond the standard regulatory process of naming a drug candidate.
Investor Verification Checklist
- Verify the correct registrant name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Confirm the status of the USAN approval for PCM-075 (Onvansertib) via the attached press release (Exhibit 99.1).
- Review the clinical development timeline for Onvansertib to understand the next regulatory milestones.
- Check subsequent filings for any financial impact or capital requirements related to advancing this specific drug candidate.